Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

27 Jan 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30690294
DOI: 10.1016/j.ejca.2018.12.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanomaPMID 30690294Read ↗

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaSemantic proximity Read ↗

Improving patient outcomes to targeted therapies in melanoma.Semantic proximity Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read ↗

The pathway ahead in melanoma trials.Semantic proximity Read ↗

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaSemantic proximity Read ↗

Community experience of vemurafenib for BRAF(V600) melanoma.Semantic proximity Read ↗

Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

DREAMseq of therapy for BRAF-mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.